Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation

Author's Avatar
Jun 16, 2021

Suicide Prevention Company Continues Experimental Validation of its >1000 Claim Patent on Application of Immunotherapy to Schizophrenia

PR Newswire